Today's PR in the first paragraph: Cytodyn...............reported today the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and faster hospital discharge in critically ill COVID-19 patients.

Isn't that rather strange, to report only critical patient data? Are we to assume the data would be worse if severe data was included? Furthermore, with only 62 critical patients, if they were to calculate a p value for critical only, the power would be so low as to certainly generate a poor p value, so, they submitted a protocol to continue the s/c trial, while simultaneously discussing/pursuing approvals in the US, Canada and the UK based upon existing data.